Therapy of Patients with T-cell Lymphomas and Leukemias Using an Anti-CD7 Monoclonal Antibody-Rich a Chain Immunotoxin

Leukemia and Lymphoma

Volumn 26, Issue 42067, 1997, Pages 287-298

  Frankel, Arthur E ^a   Laver, Joseph H ^a   Willingham, Mark C ^a   Burns, Linda J ^b   Kersey, John H ^b   Vallera, Daniel A ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

immunotoxin; Ricin; T cell lymphoma leukemia

Indexed keywords

CD7 ANTIGEN; FIBRONECTIN; IMMUNOTOXIN; MONOCLONAL ANTIBODY; RICIN;

APHASIA; ARTICLE; CONFUSION; DEGLYCOSYLATION; DYSPNEA; HUMAN; HUMAN CELL; HYPOALBUMINEMIA; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; LARGE GRANULAR LYMPHOCYTE; LUNG EDEMA; MAXIMUM PERMISSIBLE DOSE; PRIORITY JOURNAL; RHABDOMYOLYSIS; T CELL LEUKEMIA; T CELL LYMPHOMA; VASCULAR ENDOTHELIUM;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, CD7; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENDOTHELIUM, VASCULAR; FEMALE; FIBRONECTINS; HUMANS; IMMUNOTOXINS; INFUSIONS, INTRAVENOUS; LEUKEMIA, T-CELL; LYMPHOMA, T-CELL; MALE; MICE; MIDDLE AGED; RICIN;

EID: 0030847302     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428199709051778     Document Type: Article

References (30)

1. Bertnesa V., Kirsch I., Hollis G., Johnson B., Bunn P. T-cell receptor gene rearrangements as clinical markers of human T-cell lymphomas. New England Journal of Medicine 1985; 313: 534 – 538
2. Harris N., Jaffe E., Stein H., Banks P., Chan J., Cleary M., Derol G., De Wolf-Peeters C., Falini B., Gatter K., et al. Perspective: A revised European-American classification of lymphoid neoplasms. Blood 1994; 84: 1361 – 1392
3. Longu D., DeVita V., Jaffe E.,. Lymphocytic lymphomas. Cancer: Principles utid Practice of Oncology, V. DeVita, S. Hellman, S. Rosenberg, et al. J.B. Lippincott, Philadelphia 1993; 1859 – 1881
4. Frankel A., Tagge E., Willingham M. Clinical trials of targeted toxins. Seminars in Cancer Biology 1995; 6: 307 – 317
5. LeMaistre C., Rosen S., Frankel A., Kornfeld S., Saria E., Meneghetti C., Drajesk J., Fishwild D., Scannon P., Byers V. Phase 1 trial of H65-RTA immunoconjugate in patients with cutaneous T-cell lymphoma. Blood 1991; 76: 1173 – 1182
6. Waldman T., Pastan I., Gansow O., Junghans R. The multichain interleukin-2 receptor: a target for immunotherapy. Ann. Intern. Med. 1992; 116: 148 – 160
7. Kuzel T., Foss F., Hesketh P., Saleh M., Platanias L., Schwartz G., Craig F., Tolson K., Woodworth T. DAB389IL2 is well tolerated at doses inducing responses in IL-2 receptor expressing lymphomas. Blood 1993; 82 (suppl. 1) 137a
8. Aruffo A., Seed B. Molecular cloning ol two CD7 (T-cell leukemia antigen) cDNAs by a COS cell expression system. EMRO Journal 1987; 11: 3313 – 3330
9. Haynec B., Eiaenbarth G., Fauci A. Human lyniphocyte antigens: produclion of a monoclonal antibody that dcfines functional thymus-derived lymphocyte subsets. Proc. Natl. Acad. Sci. USA 1979; 76: 5829 – 5833
10. Lazarovits A., Osman N., Le Feuvre C., Ley S., Crumpton M. CD7 is associated with CD3 and CD45 on human T cells. Journal of Immunology 1994; 153: 3956 – 3966
11. Hertler A., Schlossman D., Borowitz M., Poplack D., Frankel A. A immunotoxin for the treatment of T-acute lymphoblastic leukemic meningitis studies in rhesus monkeys. Cancer Immunol. Immunother. 1989; 28: 59 – 66
12. Vallera D., Burns L., Frankel A., Sicheneder A., Kersey J. Laboratory preparation of a deglycosylated ricin toxin A chain containing imniunotoxin directed against a CD7 T lineage differentiation antigen for phase I human clinical studies involving T cell malignancies. J. Immunol. Merhods 1996; 197: 69 – 83
13. Janaen B., Vallera D., Jascz W., Nguyen D., Kersey J. Successful treatment of human acute T-cell leukemia in SCID mice using anti-CD7-deglycosylated ricin A, DA7. Cancer Research 1992; 52: 1314 – 1321
14. Lichtman S., Ratain M., Van Echo D., Rosner G., Egorin M., Budman D., Vogelzang N., Norton L., Schilsky R. Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study. JNCI 1993; 85: 1319 – 1326
15. Sausville E., Headlee D., Stetler-Stevenson M., Jaffe E., Solomon D., Figg W., Herdt J., Kopp W., Rager H., Steinberg S., Ghetie V., Schindler J., Uhr J., Wittes R., Vitetta E. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study. Blood 1995; 85: 3457 – 3465
16. Hertler A., Schlossman D., Borowitz M., Laurent G., Jansen F., Schmidt C., Frankel A. A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia. Journal of Biological Response Modjfiers 1988; 7: 97 – 113
17. Hertler A., Spitler L., Frankel A. Humoral immune response to a ricin A chain immuntoxin in patients with metastatic melanoma. Cancer Drug Delivery 1987; 4: 245 – 253
18. Amlot P., Stone M., Cunningham D., Fay J., Newman J., Collins R., May R., McCarthy M., Richardson J., Ghetie V., Ramilo O., Thorpe P., Uhr J., Vitetta E. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas re. to conventional therapy. Blood 1993; 82: 2624 – 2633
19. Grossbard M., Lambert J., Goldmacher V., Spector N., Kinsella J., Eliseo L., Coral F., Taylor J., Blattler W., Epstein C., Nadler L. Antik B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. Journal of Clinical Oncology 1993; 11: 726 – 737
20. Uckun F. Annotation: immunotoxins for the treatment of leukaemia. British Journal of Haematology 1093; 85: 435 – 438
21. Pai L., Wittes R., Setser A., Willingham M., Pastan I. Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nature Medicine 1906; 2: 350 – 353
22. Soler-Rodriguez A., Chetie M., Oppenheimer-Marks N., Uhr J., Vitetta E. Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: implications for vascular leak syndrome. Exp. Cell Res. 1993; 206: 227 – 234
23. Hertler A., Schlossman D., Borowitz M., Blythman H., Casellas P., Frankel A. An anti LCD5 immunotoxin for chronic lymphocytic leukemia: enhancement of cytotoxicity with human serum albumin-monensin. Int. J. Cancer 1989; 43: 215 – 219
24. Blakey D., Watson G., Knowles P., Thorpe P. Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibody. Cancer Research 1987; 47: 947 – 952
25. Pastan I., Pai L., Brinkmann U., Fitz Gerald D. Recombinant toxins: new therapeutic agents for cancer. Ann. N. Y. Acad. Sci. 1995; 758: 345 – 354
26. Baluna R., Ghetie V., Oppenheimer-Marks N., Vitctta E. The binding of ricin A-chain to fibronection: Implications for vascular leak syndrome in immunotoxin-treated patients. Int'l. J. Immunopharm. 1997, in press
27. Falini B., Pasqualucci L., Flenghi L., Bolognesi A., Kadin M., Stein H., Martelli M., Stirpe F. Anti-CD30 immunotoxins: experimental and clinical studies. Proc. Fourth Intl. Symposium on Immunotoxins, Myrtle Beach, 1995; 160
28. Spitler L., Del Rio M., Khentigan A., Wedel N., Brophy N., Miller L., Harkonen W., Rosendorf L., Lee H., Mischak R., Kawahata R., Stoudemire J., Fradkin L., Bautista E., Scannon P. Therapy of patients with malignant melanoma using a monoclonal anti-melanoma antibody-ricin A chain immunotoxin. Cancer Research 1987; 47: 1717 – 1723
29. Could B., Borowitz M., Groves E., Carter P., Anthony D., Weiner L., Frankel A. Phase I study of an anti-breast cancer immunotoxin by continuous infusion: report of a targeted toxic effect not predicted by animal studies. JNCI 1989; 81: 775 – 781
30. Baluna R., Sausville E., Stone M., Stetler-Stevenson M., Uhr J., Vitetta E. Decreases in levels of serum fibronectin predict the severity of vascular leak syndrome in patients treated with ricin A-chain-containing immunotoxins. Clin. Cancer Research. 1996, in press